Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Custom Spine expands board and appoints CFO

This article was originally published in Clinica

  • News

Executive Summary

Privately-held spinal implants developer Custom Spine has elected three new members to its board of directors: James Pastena, founder and CEO of neuromodulation company ElectroCare; Doug Daniels, president and CEO of hydrosurgery specialist Hydrocision; and Gualberto (Gil) Medina, who was the former Secretary of Commerce for New Jersey and a member of the Small Business Administration National Advisory Council. Mr Medina is currently executive managing director of Cushman & Wakefield, the world's largest property services firm. Custom Spine, based in Parsippany, New Jersey, also appointed David Hess as chief financial officer. Mr Hess has over 25 years' finance and accounting experience, specialising in infrastructure development and integration, enterprise turnaround and strategic planning.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

See All
UsernamePublicRestriction

Register

MT043968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By